Loading...

Intellectia LogoIntellectia
Auto Trade
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. VALN
VALN logo

VALN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Valneva SE (VALN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
10.630
1 Day change
-4.32%
52 Week Range
12.250
Analysis Updated At
2026/02/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Valneva SE (VALN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show some bullish signals, there is no significant trading trend, news, or financial data to support a strong entry point. Additionally, no proprietary trading signals or congressional trading data are available to provide further conviction.

Technical Analysis

The MACD is positive at 0.126, indicating a bullish momentum, but it is contracting. The RSI is neutral at 52.199, showing no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near a key support level (S1: 10.157). However, there is no strong confirmation of a breakout or reversal.

Positive Catalysts

  • Bullish moving averages and positive MACD suggest some upward momentum.

Neutral/Negative Catalysts

  • No recent news, financial data, or significant trading trends from hedge funds or insiders. The RSI is neutral, and there are no proprietary trading signals to support a strong buy.

Financial Performance

No financial data available for assessment.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for trend analysis or recent analyst ratings.

Wall Street analysts forecast VALN stock price to fall
2 Analyst Rating
Wall Street analysts forecast VALN stock price to fall
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 11.110
sliders
Low
7.55
Averages
10.28
High
13
Current: 11.110
sliders
Low
7.55
Averages
10.28
High
13
Guggenheim
Buy
downgrade
$14 -> $13
AI Analysis
2025-09-08
Reason
Guggenheim
Price Target
$14 -> $13
AI Analysis
2025-09-08
downgrade
Buy
Reason
Guggenheim lowered the firm's price target on Valneva to $13 from $14 and keeps a Buy rating on the shares following the company's recent first half earnings release and the suspension of the Ixchiq BLA in the U.S. Given the suspension, the firm is removing all U.S. Ixchiq sales from its model and also assumes more limited commercial uptake in Europe, but it maintains a Buy rating ahead of the "important" Phase 3 data readout for their Lyme vaccine that it expects by late Q4 or in early Q1 of 2026.
Jefferies
Maury Raycroft
Buy
downgrade
$18 -> $14
2025-08-25
Reason
Jefferies
Maury Raycroft
Price Target
$18 -> $14
2025-08-25
downgrade
Buy
Reason
Jefferies analyst Maury Raycroft lowered the firm's price target on Valneva to $14 from $18 and keeps a Buy rating on the shares after the FDA suspended the Ixchiq biologics license application based on four new serious adverse events seen outside of the U.S. The firm, which thinks there is some potential risk for ex-U.S. regulators to change their stance on Ixchiq licensure, adds that Ixchiq is "not a major revenue driver" in the near term.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for VALN
Unlock Now

People Also Watch